Pain Self reported measures FIQ pain, SF‐36 bodily pain and VAS (transformed range 0 to 100, higher scores mean more pain) · adults with fibromyalgia
1 finding from 1 review
Muscle strength · adults with fibromyalgia
1 finding from 1 review
Muscle strength · adults with fibromyalgia
1 finding from 1 review
Six‐minute walk distance · adults with fibromyalgia
1 finding from 1 review
Multidimensional function FIQ Total Score. Scale 0‐100 (lower scores indicate greater health) · adults with fibromyalgia
1 finding from 1 review
Physical function · adults with fibromyalgia
1 finding from 1 review
Withdrawals due to high blood pressure · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
High dose SSRIs versus placebo Continuous administration · women with premenstrual syndrome
The intervention probably leads to higher high dose SSRIs versus placebo Continuous administration (moderate certainty).
1 finding from 1 review
Quality of life (change from baseline) in the medium term · patients with schizophrenia or related psychoses
1 finding from 1 review
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Intervention not reported
Hospital length of stay (high‐risk surgical patients) · Adult patients in intensive care
1 finding from 1 review
Pain VAS 0‐100 (higher means worse) · patients with osteoarthritis
1 finding from 1 review
Function (short‐term) WOMAC scale from: 0 to 100 (higher is worse function). · patients with osteoarthritis
1 finding from 1 review
Functional disability at 3 months ‐ not measured · Adults with lateral elbow pain
1 finding from 1 review
Intervention not reported
Arrhythmias ‐ high risk patients · Adult patients 18 years and above undergoing elective surgery
1 finding from 1 review